Condition category
Musculoskeletal Diseases
Date applied
10/12/2014
Date assigned
04/02/2015
Last edited
04/02/2015
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Osteoarthritis (OA) is the most common disease affecting the joint. It can develop in any joint but it most often affects those that carry weight, such as the hips, spine and knees. It is caused by damage in and around the joint that can’t be fully repaired. Some of the cartilage (the protective layer covering the bones at the joint that ensures the joint moves smoothly) can become damaged or lost, leading to swelling (inflammation), pain and stiffness. Typical symptoms also include a deep, aching pain which can spread (radiate) from the affected joint, loss in the range of movement possible in the joint and the development of hard, bony, growths. Sufferers may also feel like their joints are crunching or grinding when they use them and find that they give way when weight is put on them. It is a long-term condition that can get worse over time. Treatment options include regular (sometimes prescribed) exercise, losing excess weight, drug treatments (such as painkillers and anti-inflammatories) and surgery. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to control OA symptoms. However, they are associated with a range of gastro-intestinal and cardiovascular side effects and other adverse effects on health. Due to safety concerns when taking these drugs, patients have turned to dietary supplements that claim to be beneficial in treating OA and safer than NSAIDS. This includes glucosamine sulfate (GS). Studies using GS to treat OA have suggested that this supplement can help protect joints against damage and repair damage that has been done. Glucosamine scored the highest level of evidence and strength of recommendation for knee OA symptoms in the current European League Against Rheumatism (EULAR) practice guidelines, and it is recommended by the latest Osteoarthritis Research Society International (OARSI) guidelines as a result. Other supplements that may help manage OA symptoms include methylsulfonylmethane (MSM) and boswellia acids (BA), both of which have been examined in previous studies. Here, we want to compare the benefits of taking MSM and BA with GS in mild to moderate knee OA.

Who can participate?
Adults aged between 25 and 85 years of age with OA of the knee.

What does the study involve?
Participants are randomly allocated into one of two groups. Those in group 1 (MB group) receive MSM and BA. Those in group 2 (GS group) are given GS supplements. All participants are asked to stop taking any anti-inflammatory drugs for at least 7 days before starting to take the supplements. They all undergo a clinical assessment and medical history at the time they start the treatment and then at two follow up visits, one 2 months after the treatment begins and the other after 6 months. Any participants that experience pain are allowed to take paracetamol, pyroxicam or diclofenac. Participants are also asked to write down their anti-flammatory drug use in a diary for evaluation purposes.

What are the possible benefits and risks of participating?
Both supplements are safe. Adverse effects are gastric heaviness or diarrhea.

Where is the study run from?
1. General Hospital of Bari (Italy)
2. Policlinico di Bari (Italy)

When is the study starting and how long is it expected to run for?
February 2012 to December 2014

Who is funding the study?
Laborest Spa (Italy)

Who is the main contact?
1. Professor Biagio Moretti
biagio.moretti@uniba.it
2. Dr Angela Notarnicola
angelanotarnicola@yahoo.it

Trial website

Contact information

Type

Public

Primary contact

Professor Biagio Moretti

ORCID ID

Contact details

Piazza g.cesare 11
Bari
70124
Italy
+39 (0)805592938
biagio.moretti@uniba.it

Type

Scientific

Additional contact

Dr Angela Notarnicola

ORCID ID

Contact details

Piazza g.cesare 11
Bari
70124
Italy
+39 (0)805592938
angelanotarnicola@yahoo.it

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

104/C.E. of 4th February 2013

Study information

Scientific title

Comparative Effectiveness of Methylsulfonylmethane and Boswellic Acids versus Glucosamine Sulfate in the Treatment of Mild to Moderate Knee Arthritis

Acronym

MEBAGA

Study hypothesis

The aim of the present investigation is to better characterize the symptomatic activity of Methylsulfonylmethane (MSM) and Boswellic Acids (BA) in patients with OA of the knee, in comparison with the commonly prescribed Glucosamine Sulfate (GS).

Ethics approval

Ethics Committee of General Hospital of Bari, Italy, 04/02/2013, ref. n.104/C.E.

Study design

Prospective, randomized controlled trial.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a participant information sheet

Condition

The required study population was patients affected by gonarthrosis

Intervention

Patients were randomized into two groups; the first taking the MSM and BA (MB group) and second the GS (GS group).

Intervention type

Supplement

Phase

Drug names

Primary outcome measures

Response to treatment, defined as a decrease of pain on the VAS and an improvement in the patient’s global assessment score on the LEQUESNE INDEX from baseline at 2 and at 6 months.

Secondary outcome measures

Reduction in the patients’ need to take anti-inflammatory drugs at 2 and 6 months. All analyses were performed at each FU, comparing results within each group and between the two groups.

Overall trial start date

01/02/2012

Overall trial end date

01/12/2014

Reason abandoned

Eligibility

Participant inclusion criteria

1. Men and women >25 and <86 years of age
2. A diagnosis of OA of the knee according to the criteria of the American College of Rheumatology
3. Grade 3 Kellgren and Lawrence radiographic staging, in which the severity of the arthritis is assessed on a scale from 0-4, hypothesizing a sequential evolution from the manifestation of osteophytes through a reduction in the width of the joint space, to subchondral sclerosis and finally the formation of cysts
4. Frequent joint pain (several days a week) for at least 6 months before recruitment;
5. Pain in the knee, scored at least 2 cm on a 10 centimetric visual analogic scale (VAS), where 0 means no pain and 10 is the worst pain possible;
6. A score of >2 on the Lequesne pain-function index (LI). The LI is a disease-specific validated questionnaire that poses a series of questions about pain in the knee (five questions on a scale from 0 to 2, where 0 indicates no pain and 2 intense pain), functional limitation (four questions, using the same scale) and maximum walking distance (one question, with a score from 0 to 6, where 0 indicates the ability to walk for an unlimited distance and 6, the inability to cover 100 m). The maximum worst final score is 24.
Lack of symptoms in other joints was not taken into consideration.

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

200

Participant exclusion criteria

1. Previous surgery of the affected knee
2. Disease processes such as rheumatoid arthritis, autoimmune diseases, systemic diseases, and tumors
3. Severe obesity (BMI >40 kg/m2)
4. Allergy to shellfish
5. Altered blood chemistry and kidney, liver, and metabolic (diabetes mellitus) function;
6. Intra-articular hyaluronic acid/cortisone infiltrations to the affected knee within 3 months before the start of the study
7. Systemic cortisone treatment taken within 3 months before the start of the study
8. Supplements (glucosamine, chondroitin sulfate, bromeline, etc) taken within 3 months before the start of the study (patients were also informed that they were not to be taken for the following 6 months).

Recruitment start date

01/06/2013

Recruitment end date

01/08/2014

Locations

Countries of recruitment

Italy

Trial participating centre

General Hospital of Bari
Piazza g.cesare 11
Bari
70124
Italy

Trial participating centre

Policlinico di Bari
Italy

Sponsor information

Organisation

Laborest Spa

Sponsor details

Via vicinale di Parabiago
n 22
Nerviano (Milan)
20014
Italy
+39 (0)331 748523
L.Secondini@laborest.com

Sponsor type

Industry

Website

http://www.laborest.com/

Funders

Funder type

Research organisation

Funder name

Laborest Spa (Italy)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

We plan to submit an article to publish in BMC Journals (for example, BMC Complementary and Alternative Medicine).

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes